XML 25 R18.htm IDEA: XBRL DOCUMENT v3.19.3
11. Segment Information Segment Reporting
 9 Months Ended
Sep. 30, 2019
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block] SEGMENT INFORMATION

Information regarding industry segments for the three months ended September 30, 2019 and 2018 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2019
$
215.7

 
$
341.8

 
$
3.1

 
2018
$
206.6

 
$
334.0

 
$
4.5

 
 
 
 
 
 
 
Segment net profit (loss)
2019
$
11.6

 
$
43.8

 
$
(0.4
)
 
2018
$
10.2

 
$
22.4

 
$
0.1


Information regarding industry segments for the nine months ended September 30, 2019 and 2018 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2019
$
643.9

 
$
1,032.9

 
$
10.4

 
2018
$
622.2

 
$
1,038.8

 
$
11.6

 
 
 
 
 
 
 
Segment net profit (loss)
2019
$
45.9

 
$
117.1

 
$
(1.1
)
 
2018
$
25.7

 
$
86.8

 
$
0.1


Information regarding industry segments at September 30, 2019, and December 31, 2018 is as follows (in millions):

 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment assets
September 30, 2019
$
500.0

 
$
1,085.6

 
$
7.8

 
December 31, 2018
$
450.2

 
$
949.0

 
$
5.9


Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance.  Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker.  Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. For the three months ended September 30, 2019 compared to the same period in 2018, our Life Science segment had increased sales, partially offset by increased cost of goods sold and selling, general and administrative expense, while our Clinical Diagnostics segment had increased sales, decreased cost of goods sold, along with decreased selling, general and administrative expense. For the nine months ended September 30, 2019 compared to the same period in 2018, our Life Science segment had increased sales and decreased cost of goods sold, partially offset by increased research and development expense, while our Clinical Diagnostics segment had decreased sales, offset by decreased cost of goods sold, selling, general and administrative and research and development expenses. Segment assets at September 30, 2019 increased from December 31, 2018 balances due to inclusion of operating lease right-of-use assets in segment assets (see Note 14, "Leases"). The following reconciles total segment profit to consolidated (loss) income before income taxes (in millions):
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2019
 
2018
 
2019
 
2018
Total segment profit
$
55.0

 
$
32.7

 
$
161.9

 
$
112.6

Foreign currency exchange losses, net
(0.9
)
 
(0.7
)
 
(3.4
)
 
(1.9
)
Net corporate operating, interest and other expense not allocated to segments
(3.1
)
 
(2.5
)
 
(8.8
)
 
(6.7
)
Change in fair market value of equity securities
(390.6
)
 
318.0

 
1,385.0

 
1,420.3

Other income (expense), net
4.4

 
2.6

 
27.0

 
29.6

Consolidated (loss) income before income taxes
$
(335.2
)
 
$
350.1

 
$
1,561.7

 
$
1,553.9



The following reconciles total segment assets to consolidated total assets (in millions):
 
September 30, 2019
 
December 31, 2018
Total segment assets
$
1,593.4

 
$
1,405.1

Cash and other current assets
1,103.6

 
1,047.2

Property, plant and equipment, net, excluding
 
 
 
  segment specific gross machinery and equipment
64.0

 
79.9

Goodwill, net
264.1

 
219.8

Other long-term assets
4,152.0

 
2,859.1

Total assets
$
7,177.1

 
$
5,611.1